- Report
- March 2025
- 194 Pages
Global
From €3371EUR$3,545USD£2,834GBP
€3745EUR$3,939USD£3,149GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,958GBP
- Report
- March 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- February 2025
- 150 Pages
Global
From €4611EUR$4,850USD£3,878GBP
- Report
- June 2024
- 200 Pages
Global
From €7559EUR$7,950USD£6,356GBP
- Report
- May 2024
- 200 Pages
Global
From €3946EUR$4,150USD£3,318GBP
- Report
- November 2021
- 120 Pages
Global
From €4279EUR$4,500USD£3,598GBP
- Report
- January 2022
- 60 Pages
Global
From €3756EUR$3,950USD£3,158GBP
Alpha Mannosidosis is a rare genetic disorder that affects the body's ability to break down certain sugars. Endocrine and Metabolic Disorders Drugs are used to treat this disorder. These drugs are designed to reduce the amount of sugar in the body, as well as to help the body break down the sugar more efficiently. Common drugs used to treat Alpha Mannosidosis include enzyme replacement therapy, gene therapy, and other medications.
The Alpha Mannosidosis Drug market is a small but growing market, with a focus on providing treatments for this rare disorder. Companies in this market are focused on developing treatments that are safe and effective, as well as providing support for patients and their families. Some of the companies in this market include Genzyme, Shire, and Sanofi. Show Less Read more